कोशिश गोल्ड - मुक्त
Mideast escalation may drive correction in overvalued India stocks
Mint Ahmedabad
|June 16, 2025
FPIs are staying away due to expensive valuations. Most FPIs are awaiting a correction in India Pratik Gupta CEO & co-head, Kotak Institutional Equities
An escalation of hostilities in the Middle East makes India vulnerable to oil price shocks and could result in a correction in stock prices, which already seem overvalued based on earnings estimates for the current fiscal, according to Pratik Gupta, chief executive officer and co-head of Kotak Institutional Equities.
Gupta said this could cap market upside over the next few months but expects earnings to pick up in the second half of the current fiscal. Foreign portfolio investors acknowledge India's strong macros and resilience of domestic flows, but await a correction to make large fresh investments, he said.
Edited excerpts:
Nifty earnings in FY25 grew in modest single digits, reflected in market valuations correcting from October to March. Our GDP growth is slated at 6.5% and inflation at 3.7% for the current fiscal, per the central bank. That means nominal growth of around 10%. How do you see Nifty and the broader market earnings pan out this fiscal year in this context? Do you expect the correction in markets since October to continue, or is the worst behind us?
We expect net profits of the Nifty 50 Index to grow 12% in FY26 and 15% in FY27, following a modest 6.4% growth in FY25. Diversified financials, metals & mining, oil, gas & consumable fuels and telecom will provide the bulk of the incremental profits for FY26 of the Nifty 50 Index. The sector-wise trends for the broader Kotak coverage universe of almost 300 companies are very similar to the sector-wise trends for the Nifty 50 Index. We estimate that the metals & mining sector will account for 22% and 16% of the incremental profits of FY26 of the Nifty 50 Index and KIE coverage universe, respectively.
यह कहानी Mint Ahmedabad के June 16, 2025 संस्करण से ली गई है।
हजारों चुनिंदा प्रीमियम कहानियों और 10,000 से अधिक पत्रिकाओं और समाचार पत्रों तक पहुंचने के लिए मैगज़्टर गोल्ड की सदस्यता लें।
क्या आप पहले से ही ग्राहक हैं? साइन इन करें
Mint Ahmedabad से और कहानियाँ
Mint Ahmedabad
'If you're on trend, you are in trouble'
Patou creative head Guillaume Henry discusses the essence of couture and why simple is best
4 mins
December 13, 2025
Mint Ahmedabad
GST cuts, easing inflation drive rural demand revival
India’s rural economy expanded and recovered strongly in late 2025, with consumption, incomes and investment improving after a key tax reform and as inflation eased, a survey showed.
2 mins
December 13, 2025
Mint Ahmedabad
Chair man, of the bored
STREAM OF STORIES
3 mins
December 13, 2025
Mint Ahmedabad
Anju Dodiya creates disquieting worlds
Artist Anju Dodiya discusses the ideas, influences and inspiration behind her new solo show, 'The Geometry of Ash'
5 mins
December 13, 2025
Mint Ahmedabad
Bar hopping with Lounge
\"The things that make a cocktail really great are often very simple details—the frozen glass, the lemon twist—that transform two fingers of alcohol into an ice-glazed elixir,\" writes Alice Lascelles in her excellent guide to making cocktails at home, The Cocktail Edit.
1 mins
December 13, 2025
Mint Ahmedabad
New Delhi and France revise 1992 tax treaty
India and France have struck a deal to revise their 1992 treaty which will halve the tax on dividends paid by Indian units to French parents, potentially saving millions for companies with major operations in the South Asian nation, documents show.
1 min
December 13, 2025
Mint Ahmedabad
Ozempic debuts with a ₹2,200-a-week price tag
for chronic weight management, Novo Nordisk is positioning Ozempic as a treatment of type 2 diabetes with weight loss benefits, competing with Eli Lily’s Mounjaro that was launched in India in March.
1 mins
December 13, 2025
Mint Ahmedabad
How 'puri-aloo' and 'chaat' unite Lucknow
Whenever my friends want to eat puri-aloo, they invite themselves over to my home.
5 mins
December 13, 2025
Mint Ahmedabad
Novo Nordisk debuts Ozempic at ₹2,200 a week
Danish drugmaker Novo Nordisk on Friday launched its blockbuster diabetes drug Ozempic in India, with a starting price of ₹2,200 per week.
1 mins
December 13, 2025
Mint Ahmedabad
Govt’s insurance reform allows 100% FDI, composite licences
The government has paved the way for 100% foreign direct investment in the insurance sector, composite licences and easier capital requirements, among others sweeping reforms, as the Union cabinet cleared the enabling legislation, said two officials aware of the matter.
1 mins
December 13, 2025
Listen
Translate
Change font size
